WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT

Product: Wondfo Malaria P.f (HRP2/pLDH) Test WHO reference number: PQDx 0651-004-00

Wondfo Malaria P.f (HRP2/pLDH) Test with product codes W037P0022 W037P0028 W037P0030, W037P0024, W037P0033, W037P0035, and W037P0037, manufactured by Guangzhou Wondfo Biotech Co., Ltd, Rest-of-World version, was accepted for the WHO list of prequalified in vitro diagnostics and was listed on 30 July 2024.

Summary of WHO prequalification assessment for the Wondfo Malaria P.f (HRP2/pLDH) Test

	Date	Outcome
Prequalification listing	30 July 2024	listed
Dossier assessment	29 July-2024	MR
Site inspection(s) of quality	13 February 2024	MR
management system		
Product performance	Quarter 4 2022	MR
evaluation		

MR: Meets Requirements

Intended use

According to the intended use claim from Guangzhou Wondfo Biotech Co., Ltd, "The Wondfo Malaria P.f (HRP2/pLDH) Test is an immunochromatographic, rapid diagnostic assay intended for the qualitative detection of P. falciparum specific histidine rich protein-2 (P.f HRP2) and P. falciparum specific pLDH (P.f pLDH) in human fingerstick whole blood and venous whole blood. It is intended to be used by laboratory professionals and at point-of-care by healthcare workers or trained lay providers. It is used as an aid for diagnosis of P. falciparum Malaria infection for symptomatic patients including paediatric testing. Results from the Wondfo Malaria P.f (HRP2/pLDH) Test should not be used as the sole basis for diagnosis.

For in vitro diagnostic use only. For professional use only."

Assay description

According to the claim of assay description from Guangzhou Wondfo Biotech Co., Ltd, "The Wondfo Malaria P.f (HRP2/pLDH) Test utilizes the principles of immunochromatography to detect two targets: P. falciparum specific histidine rich protein-2 (P.f HRP2) and P. falciparum specific pLDH (P.f pLDH) in human fingerstick whole blood and venous whole blood.

After adding specimen into the sample well and adding buffer int o the b u f fer wel I, the specimen-buffer mixture migrates towards the other end of the cassette by capillary action. The antigen in the specimen will bind the antibody-gold colloid to form the antigenantibody-gold colloid complex.

The complex migrates further to capture P.f HRP2 specific antibody / P.f pLDH specific antibody that is pre-coated on the test line of the cassette. When a target antigen (P.f HRP2 and/or P.f pLDH) level is at or above the limit of detection (LoD) of the assay, the test line will form a visible red line, indicating a positive result.

Rabbit IgG-gold colloid combines with goat anti-rabbit IgG polyclonal antibody in C line (control line) to form a red reaction line. The control line is used for procedural control and shows only that the buffer has been applied successfully and that the active ingredients of the main components on the strip are functional."

Component	25 Tests(T) (W037P0022)	40 T (W037P0024)	25 T (W037P0028)	25 T (W037P0030)	40 T (W037P0033)	40 T (W037P0035)	100 T (W037P0037)
Cassette (pieces (pcs)	25	40	25	25	40	40	100
Instructions	1	1	1	1	1	1	1
Buffer	25×0.3 mL/vial	40×0.3 mL/vial	2×5 mL/bottle	2×5 mL/bottle	4×5 mL/bottle	4×5 mL/bottle	8×5 mL/bottle
Quick guide (pcs)	25 pouches, each	40 pouches, each	/	/	/	/	/
Inverted cup (pcs)	containing one	containing one quick guide:	25	25	40	40	100
Alcohol prep pad (pcs)	quick guide: one	one inverted cup,	25	25	40	40	100
Sterile lancet (pcs)	inverted cup, one alcohol prep pad, one sterile lancet.	one alcohol prep pad, one sterile lancet.	25	/	40	/	100
Blood lancet for single use (pcs)	/	/	/	25	/	40	/

Test kit contents

Items required but not provided

- Timer
- Protective gloves
- Specimen and test waste container
- Sterile cotton swab/ball
 - Note: If whole blood is collected by venipuncture, venipuncture blood collection materials are required in addition to a precision pipette and pipette tips.

Storage

The test kit should be stored at 1-40 °C.

Shelf-life upon manufacture

24 months.

Warnings/limitations

Refer to the current version of the manufacturer's instructions for use attached to this public report.

The WHO Global Malaria Programme recommends the use of tests detecting pLDH and a panel detection of at least 75% on the panel of nonHRP2 expressing specimens in areas with high prevalence of *pfhrp2/3* gene deletions¹. This test does not meet these criteria and is not recommended for use in such settings.

Prioritization for Prequalification Assessment

Based on the established eligibility criteria, Wondfo Malaria P.f (HRP2/pLDH) Test was given priority for WHO prequalification assessment.

Dossier assessment

Guangzhou Wondfo Biotech Co., Ltd submitted a product dossier for the Wondfo Malaria P.f (HRP2/pLDH) Test as per the "Instructions for compilation of a product dossier" (PQDx_018). The information (data and documentation) submitted in the product dossier was reviewed by WHO staff and external technical experts (assessors) appointed by WHO. The manufacturer's responses to the nonconformities found during dossier screening and assessment findings were accepted on 29 July 2024.

Commitment for prequalification

The manufacturer will provide additional information regarding accuracy of measurement and additional details regarding the analytical specificity study report.

Based on the product dossier screening and assessment findings, the product dossier for the Wondfo Malaria P.f (HRP2/pLDH) Test meets WHO prequalification requirements.

¹ https://iris.who.int/bitstream/handle/10665/258972/WHO-HTM-GMP-2017.18-eng.pdf?sequence=1

Manufacturing site inspection

At the time of considering the product application for Prequalification, the Manufacturer of the product had a well-established quality management system and manufacturing practices in place that would support the manufacture of a product of consistent quality. Routine inspections of the Manufacturing site will be conducted with copies of the WHO Public Inspection Report (WHOPIR) published on the WHO Prequalification web page as per Resolution WHA57.14 of the World Health Assembly. Note that a WHOPIR reflects the information on the most current assessment performed at a manufacturing site for in vitro diagnostic products and summarises the assessment findings.

https://extranet.who.int/pqweb/vitro-diagnostics/who-public-inspection-reports

All published WHOPIRs are with the agreement of the manufacturer.

Based on the site inspection and corrective action plan review, the quality management system for the **Wondfo Malaria P.f (HRP2/pLDH) Test** meets WHO prequalification requirements.

Product performance evaluation

Wondfo Malaria P.f (HRP2/pLDH) Test (Guangzhou Wondfo Biotech Co., Ltd.) was evaluated by the Centers for Disease Control and Prevention on behalf of WHO in the fourth quarter of 2022, according to protocol PQDx_317, version 3.1.

Clinical performance evaluation

Wondfo Malaria P.f (HRP2/pLDH) Test was evaluated against a *Plasmodium falciparum* cultured line panel, *P. falciparum* wild type parasite panel, *P. vivax* wild type parasite panel, *hrp2/3* deletion panel, a parasite-negative panel (including clean negatives from afebrile donors and specimens with possible cross-reactants), and the WHO International standard for *P. falciparum* antigens.

Performance characteristics				
	P. falciparum	P. vivax	Pf – <i>hrp2</i> deletion panel	
Panel detection score [#] at 200 parasites/µL	93/100, 93.0 %	NA	21/60, 35.0%	
Proportion detected by line at 200 parasites/µL	HRP2 line: 98.0% Pf-pLDH line: 55.0% (N=400)	NA	HRP2 line: 16.7% Pf-pLDH line: 52.5% (N=240)	

False positive results %	All negative specimens: 0/200, 0.0% Of which, clean negative specimens: 0/104, 0% No false Pf result on the <i>P. vivax</i> specimens at 200 and 2000 parasites/µL		
Invalid rate % (N= 1322)	0/1322, 0.0 %		
Inter-reader variability on the wild-type and negative panels % (N= 1010)			
Lowest concentration of HRP2/pLDH detected using the 1 st WHO International standard for Pf antigens (NIBSC code: 16/376)*	HRP2 test line: Lot A: 7.8 IU/mL Lot B: 3.9 IU/mL	Pf-pLDH test line: Lot A: 15.6 IU/mL Lot B: 15.6 IU/mL	

The panel detection score is the proportion of specimens at a specified concentration that gave positive results in all 4 tests performed with this specimen (2 tests on each of 2 lots).

* Not applicable for assays evaluated in WHO product testing of RDTs for malaria antigen detection.

Operational characteristics and ease of use

This assay does not require laboratory equipment and can be performed in laboratories with limited facilities or in non-laboratory settings.

The assay was found easy to use by the operators performing the evaluation.

However, the operators noted that 383/1010 (37.9 %) of the tests performed on the wild-type and negative panels showed anomalies (234 with incomplete clearing, 38 with red background, 51 with red background obscuring test line, 58 with patchy line, 1 with strip misplaced, and 1 with failed migration).

Key operational characteristics	
Specimen type and volume	5 μL of fingerstick whole blood or venous whole blood collected into a blood collection tube with anticoagulant (EDTA, sodium citrate, or heparin sodium)
Number of steps*	2 steps in total 1 step with specimen transfer device (precision pipette was used during the evaluation)
Time to result	15 minutes
Endpoint stability (interval)	15 minutes (the test can be read between 15 and 30 minutes after addition of diluent)
Internal QC	Yes, reagent addition control

* Definition: each action required to obtain a result (excluding specimen collection, device preparation – opening the pouch), e.g. for RDTs: add specimen, add buffer (2 steps).

Based on these results, the performance evaluation for meets the WHO prequalification requirements.

Labelling

- 1. Labels
- 2. Instructions for use

1. Labels

1.1 Labels and packaging artwork for 25 Tests(T) (W037P0022)

Wondfo Malaria Image: Constant of the system of the sy















Image:	Image:

1.2 Labels and packaging artwork for 40 T (W037P0024)

Wondfo Malaria P.f (HRP2/pLDH) Test

CONTENTS:

- 1. 40 Individual pouches, each containing: Test cassette
- Desiccant pouch 2. 40 Vials of P.f buffer (0.3mL/vial)
- 3. 1 Instruction for use
- 4. 40 Alcohol prep pads5. 40 Sterile lancets
- 6. 40 Inverted cups
- 7. 40 Quick guides

Version: A2 Rel.:2024/06/25

 \sum_{40}

















Image: Second system Image: Second system Image: Second system ART NO.: Image: Second system Image: Second system C/NO.: Image: Second system Image: Second system QTY: PCS Image: Second system QTY: PCS N.W: KGS G.W: KGS MEAS: 58.7×47.7×40.2 CM	Image: Image

1.3 Labels and packaging artwork for 25 T (W037P0028)

Wondfo Malaria P.f (HRP2/pLDH) Test

CONTENTS:

- 1. 25 Individual pouches, each containing: Test cassette
 - Desiccant pouch
- 2. 2 Bottles of buffer (5mL/bottle)
- 3.1 Instruction for use
- 4. 25 Alcohol prep pads
- 5. 25 Sterile lancets
- 6. 25 Inverted cups

Version: A2 Rel.: 2024/06/25

 $\overline{\sum}_{25}$















size:38*20mm

Buffer for Wondfo Malaria P.f (HRP2/pLDH) Test Lot:XXXXXXXX Ref: W037P0028 Exp: YYYY-MM-DD Vol5ml Store at:1-40°C Version/A2 Rel:2024/06/25

size:38*20mm





1.4 Labels and packaging artwork for 25 T (W037P0030)

Wondfo Malaria P.f (HRP2/pLDH) Test

CONTENTS:

- 1. 25 Individual pouches, each containing:
 - Test cassette Desiccant pouch
- 2. 2 Bottles of buffer (5mL/bottle)
- 3. 1 Instruction for use
- 4. 25 Alcohol prep pads
- 5. 25 Blood lancets for single use
- 6. 25 Inverted cups

Version: A3 Rel.: 2024/06/25

 \sum_{25}














Buffer for Wondfo Malaria P.f (HRP2/pLDH) Test Lot:XXXXXXXX Ref: W037P0030 Exp: YYYY-MM-DD Vot5ml Store at:1-40°C Version:A2 Rel:2024/06/25





1.5 Labels and packaging artwork for 40 T (W037P0033)

Wondfo Malaria P.f (HRP2/pLDH) Test

CONTENTS:

- 1. 40 Individual pouches, each containing: Test cassette
 - Desiccant pouch
- 2. 4 Bottles of buffer (5mL/bottle)
- 3.1 Instruction for use
- 4. 40 Alcohol prep pads
- 5. 40 Sterile lancets
- 6. 40 Inverted cups

Version: A2 Rel.: 2024/06/25

Σ_40















Buffer for Wondfo Malaria P.f (HRP2/pLDH) Test Lot:XXXXXXXX Ref: W037P0033 Exp: YYYY-MM-DD Vol5ml Store at:1-40°C Version/A2 Rel:2024/06/25





500mm

630mm

1.6 Labels and packaging artwork for 40 T (W037P0035)

















Buffer for Wondfo Malaria P.f (HRP2/pLDH) Test Lot:XXXXXXXX Ref: W037P0035 Exp: YYYY-MM-DD Vol5ml Store at:1-40°C Version/A2 Rel:2024/06/25





500mm

630mm

1.7 Labels and packaging artwork for 100 T (W037P0037)
















size:38*20mm

Buffer for Wondfo Malaria P.f (HRP2/pLDH) Test Lot:XXXXXXXX Ref: W03790037 Exp: YYYY-MM-DD Vol5ml Store at:1-40°C Version/A2 Rel:2024/06/25

size:38*20mm



Image:	ART NO.: C/NO.: C/NO.: QTY: PCS N.W: KGS G.W: KGS MEAS: 61×46.4×48.4 CM

2.1 Instructions for use²

 $^{^2}$ English version of the IFU was the one that was assessed by WHO. It is the responsibility of the manufacturer to ensure correct translation into other languages.

ll/ondfo

Wondfo Malaria P.f (HRP2/pLDH) Test

CATALOG No.

W037P0022	W037P0028	W037P0030
W037P0024	W037P0033	W037P0035
W037P0037		

INTENDED USE

The Wondfo Malaria P.f (HRP2/pLDH) Test is an immunochromatographic, rapid diagnostic assay intended for the qualitative detection of P. falciparum specific histidine rich protein-2 (P.f HRP2) and P. falciparum specific pLDH (P.f pLDH) in human fingerstick whole blood and venous whole blood. It is intended to be used by laboratory professionals and at point-of-care by healthcare workers or trained lay providers. It is used as an aid for diagnosis of P. falciparum Malaria infection for symptomatic patients including paediatric testing. Results from the Wondfo Malaria P.f (HRP2/pLDH) Test should not be used as the sole basis for diagnosis.

For in vitro diagnostic use only. For professional use only.

BACKGROUND INFORMATION

Malaria remains one of the most serious tropical diseases in many regions of the world, mainly occurring in tropical and subtropical areas. Malaria is caused by a parasite that commonly infects the Anopheles mosquito which feeds on human blood. There are four kinds of malaria parasites that can infect humans: P. falciparum, P. vivax, P. malariae.

and P. ovale. Malaria can also be transmitted through blood transfusions, organ transplantation or shared needles/syringes contaminated with blood from an infected person. It can also be transmitted congenitally from mother to her unborn infant. It is estimated to affect more than 200 million people worldwide and cause more than 400,000 deaths every year [1,4,5].

PRINCIPLES OF THE PROCEDURE

The Wondfo Malaria P.f (HRP2/pLDH) Test utilizes the principles of immunochromatography to detect two targets: P. falciparum specific histidine rich protein-2 (P.f HRP2) and P. falciparum specific pLDH (P.f pLDH) in human fingerstick whole blood and venous whole blood.

After adding specimen into the sample well and adding buffer into the buffer well, the specimen-buffer mixture migrates towards the other end of the cassette by capillary action. The antigen in the specimen will bind the antibody-gold colloid to form the antigen-antibody-gold colloid complex. The complex migrates further to capture P.f HRP2 specific antibody / P.f pLDH specific antibody that is pre-coated on the test line of the cassette. When a target antigen (P.f HRP2 and/or P.f pLDH) level is at or above the limit of detection (LoD) of the assay, the test line will form a visible red line, indicating a positive result.

Rabbit IgG-gold colloid combines with goat anti-rabbit IgG polyclonal antibody in C line (control line) to form a red reaction line. The control line is used for procedural control and shows only that the buffer has been applied successfully and that the active ingredients of the main components on the strip are functional.

WARNINGS AND PRECAUTIONS

- 1. This kit is for in vitro use only.
- 2. Apply standard biosafety precautions for handling and disposal of potentially infective material
- Handle all specimens as potentially infectious.
- Wear gloves while handling specimens and performing the test.
- Avoid splashing and aerosol formation.
- Clean up spills thoroughly using an appropriate disinfectant
- 3. Do not reuse the test cassette, inverted cup, lancet, and alcohol prep pad.
- 4. Do not use the kit beyond the expiration date.
- 5. Do not use the test cassette if the pouch is punctured or improperly sealed.
- 6. **Do not** mix a buffer and a test cassette from different lots.
- 7. Do not open the sealed pouch until you are ready to conduct the assay. Once opened, use the test cassette within 1 hour.
- 8. Decontaminate and dispose of all specimens, reaction kits and potentially contaminated materials as biohazardous waste.
- 9. Read the instructions for use completely before using the kit. Failure to follow directions may yield inaccurate test results.
- 10. DISPOSAL OF DIAGNOSTIC DEVICE: The used device has risk of infection. The process for disposing the diagnostic device must follow local infectious waste disposal laws or laboratory regulations.
- 11. Keep out of reach of children.
- 12. The Buffer contains 2% Triton X-100, which presents no hazard to the user if normal laboratory safety precautions are followed. Wear protective gloves. In case of contact with skin

and/or the eyes, rinse with water immediately. If irritation or signs of toxicity occur, seek medical attention. Follow local regulation or laws to dispose the Buffer.

KIT CONTENTS

There are 7 configurations of the test kits. The inclusion of quick quide, sterile lancet or blood lancet for single use are optional/available in different combinations per end user's request.

A. Kit components

Each individually sealed pouch contains one test cassette and one desiccant pouch (for storage purposes only).

The kit component configurations are provided below:

Catalogue No.	W037P0022	W037P0024	W037P0028	W037P0030	W037P0033	W037P0035	W037P0037
Components	W037F0022	W037F0024	W037F0028	W037P0030	W037F0033	W037F0033	W037P0037
Cassette (pcs)	25	40	25	25	40	40	100
Instruction (pcs)	1	1	1	1	1	1	1
Buffer	25×0.3mL/vial	40×0.3mL/vial	2×5mL/bottle	2×5mL/bottle	4×5mL/bottle	4×5mL/bottle	8×5mL/bottle
Quick guide (pcs)	25 pouches, each	40 pouches, each	/	/	/	/	/
Inverted cup (pcs)	containing one quick guide, one	containing one quick guide, one	25	25	40	40	100
Alcohol prep pad (pcs)	inverted cup,one alcohol prep pad,	inverted cup, one alcohol prep pad,	25	25	40	40	100
Sterile lancet (pcs)	one sterile lancet.	one sterile lancet.	25	/	40	/	100
Blood lancet for single use(pcs)	/	/	/	25	/	40	/

B. Reactive ingredients of main components

The test strip is coated with gold conjugates (Malaria P.f HRP2 monoclonal antibody-gold colloid Malaria P.f pLDH monoclonal antibody-gold colloid, rabbit IgG-gold colloid), test line (Malaria P.f HRP2 monoclonal antibody and Malaria P.f pLDH monoclonal antibody) and control line (goat anti-rabbit IgG polyclonal antibody).

MATERIALS REQUIRED BUT NOT PROVIDED

- 1. Timer
- 2. Protective gloves
- Specimen and test waste container
 - 4. Sterile cotton swab/ball

Note: If whole blood is collected by venipuncture, venipuncture blood collection materials are required in addition to a precision pipette and pipette tips.

- STORAGE AND STABILITY
- 1. Store the kit at 1°C-40°C. The shelf life of the kit is 24 months.
- 2. Use the test cassette within 1 hour after opening.
- For 0.3 mL buffer, discard after every use. For 5 mL buffer. store at 1°C-40°C for no more than 8 weeks after opening.

- 3. Use the kit at 20%-90% humidity and 15°C-40°C,
- on a clean and flat surface.
- Recap and store the buffer (5mL) in the original container after use.
- 5. Keep away from sunlight, moisture, and heat.
- 6. Do not freeze.

SPECIMEN COLLECTION AND PREPARATION

Fingerstick whole blood:

- 1. Wash hands and put on protective gloves. Select the middle or ring finger of the patient and avoid calloused areas of the finger. Clean the finger to be lanced with an alcohol prep pad.
- 2. Prick the lateral side of fingertip with a lancet. Gently squeeze the end of fingertip and wipe off the first drop of blood with a sterile cotton swab/ball. Squeeze the fingertip again and allow a new drop of blood to form.
- 3. Draw 5 microliter (5µL) of blood with an inverted cup. Test immediately after whole blood specimens collected by fingerstick.

Venous whole blood:

- Draw venous whole blood via standard phlebotomy procedures into a blood collection tube with anticoagulant (EDTA, sodium citrate, or heparin sodium).
- 2. If immediate testing is not possible then the specimen may be stored at 2°C-8°C for up to 72 hours before testing.
- 3. The specimens should be stored at -70°C or below for longer storage.

Note:

- 1.Prior to testing, bring specimens to room temperature slowly and mix well gently once thawed. Do not freeze and thaw the specimens repeatedly. In case repeated freezing and thawing of specimens is required, no more than 5 cycles should be allowed
- 2. To ensure the accuracy of test result, whole blood specimens partly or completely coagulated should be excluded even though they are not validated.

TEST PROCEDURE

Bring all specimens and kit components to room temperature (15°C- 40°C) before testing. When ready to test, remove the test cassette from the foil pouch by tearing the notch and place it on a flat, dry

surface. Label the device with specimen ID number.

For 0.3mL buffer configurations, please refer to QUICK GUIDE. For 5mL buffer configurations, please follow the instruction as below.

1. Test procedure for fingerstick whole blood

A. Wash hands and put on protective gloves before testing. Wipe the fingertip to be lanced with an alcohol prep pad.Select the middle or ring finger for sampling and avoid calloused areas of the finger.



B. Prick the lateral side of fingertip with a lancet. Wipe off the first drop of blood with a sterile cotton swab/ball.Squeeze the fingertip again and allow a new drop of blood to form.



C. Dip the circular end of the inverted cup into the blood specimen (5µL).



D. Place the circular end of the inverted cup into the sample well.



E. Add 4 drops (about 100µL) of buffer into the buffer well vertically and start timing.



2. Test procedure for venous whole blood

A. Please gently mix the venous blood specimen by inverting the blood collection tube to make it homogenous. Take 5µL venous whole blood specimen with a pipette and drop it into the center of the sample well vertically.



B. Add 4 drops (about 100µL) of buffer into the buffer well vertically, and start timing.



3. Interpretation

- A. Read the results after 15 minutes but no more than 30 minutes.
- B. To avoid confusion, discard the test device after reading the result.



15-30 mins

OUALITY CONTROL

- 1. Internal control: This kit contains a built-in control feature as a procedural control, the control region (C). A colored line develops in the control region (C) after addition of the specimen and buffer. If a colored line does not-develop in the C region, the test is invalid. Review the procedure and repeat the test with a new device.
- 2. External control: The test kit does not provide external control

INTERPRETATION OF RESULTS



T2

Result: Negative. Action: No

Lines that you see	Picture	Read and Interpretation of Results
	1 C T2 T1	Result: Positive. 1. Line at 'C', 'T1' and 'T2' indicates positive for P.f HRP2 and P.f pLDH.
Line at 'C' and at 'T1' and/or 'T2'	2 C T2 T1	 2. Line at 'C' and 'T1' indicates positive for P.f HRP2. 3. Line at 'C' and 'T2' indicates positive for P.f pLDH.
	3 C T2 T1	Note: Line intensity may vary from faint to strong intensity. Consider a faint test line as a positive result. Action: No

Note: Please contact the local distributor or manufacturer if there is suspicion of an increased rate of false negative or positive results.

LIMITATIONS OF PROCEDURE

- 1. The kit is a qualitative assay designed to detect P. falciparum specific histidine rich protein-2 (P.f HRP2) and P. falciparum specific pLDH (P.f pLDH) antigens in human whole blood only.
- 2. Strictly operate according to the instructions for use when testing. False operation will result in a false result
- 3. Use EDTA, heparin sodium, and sodium citrate as anticoagulants. Do not use other anticoagulants.
- 4. False-negative results can occur in the following conditions:
- · Very low antigen concentrations/parasite densities, for instance < 100 parasites/ µl. Note that most clinical cases have higher parasite densities.
- Very high parasite densities (very exceptional, prozone or high-hook effect) for the HRP2 antigen.
- · Deletions in the HRP2 gene result in no production of the HRP2 antigen, which is of particular relevance for mRDTs that detect this antigen. These deletions were first identified in the Peruvian Amazon but have since been reported in various malaria-endemic regions worldwide.
- High fraction of interstitial fluid due to "milking" of fingertip.
- 5. The presence of the control line only means that migration of added liquid occurred. It does not quarantee that:
- The correct specimen has been used.
- The specimen has been applied correctly.
- The specimen and kit have been correctly stored The test procedure has been followed correctly.
- 6. As with all diagnostic tests, a definitive clinical diagnosis should not be based on the result of a single test but instead should be determined by a healthcare provider in conjunction with clinical findings and the results from other laboratory tests and evaluations. Results from the Wondfo Malaria P.f (HRP2/pLDH) Test should not be used as the sole basis for diagnosis.
- 7. The product can give a false positive Pf result even after the patient was treated for malaria several weeks before testing. The test cannot be used to monitor treatment response to antimalarials

PERFORMANCE CHARACTERISTICS^[2,3]

Clinical performance study

1. Internal Evaluation

Place of	SD	W	ondfo Mala	aria P.f	(HRP2/pLDH) Test
Evaluation	Bioline	Positive	Negative	Total	Test Result (95% CI)
Wondfo	P.f Positive	102	0	102	Sensitivity:100.00% (96.37-100.00%)
laboratory	P.f Negative	1	625	626	Specificity:99.84% (99.10-99.97%)

*Specimen type used for SD Bioline and Wondfo: venous whole blood.

2. External Evaluation

2.1 Diagnostic Sensitivity and Specificity

Place of	SD	Woi	ndfo Malar	ia P.f (H	HRP2/pLDH) Test
Evaluation		Positive	Negative	Total	Test Result (95% CI)
Cote	P.f Positive	183	0	183	Sensitivity:100.00% (97.94~100.00%)
d'Ivoire	P.f Negative	3	354	357	Specificity:99.16% (97.56~99.71%)
Rwanda	P.f Positive	175	0	175	Sensitivity:100.00% (97.85~100.00%)
Rwallua	P.f Negative	0	364	364	Specificity:100.00% (98.96~100.00%)
Cameroon	P.f Positive	133	0	133	Sensitivity:100.00% (97.19~100.00%)
Cameroon	P.f Negative	1	375	376	Specificity:99.73% (98.51~99.95%)

*Specimen type used for SD Bioline: venous whole blood; Specimen type used for Wondfo: fingerstick whole blood.

2.2 Comparison with PCR assay

Place of		Wo	ndfo Malar	ia P.f (H	IRP2/pLDH) Test
Evaluation	PCR	Positive	Negative	Total	Test Result (95% CI)
Cote	P.f Positive	117	1	118	Sensitivity: 99.15% (95.37%-99.98%)
d'Ivoire	P.f Negative	67	353	420	Specificity: 84.05% (80.19%-87.42%)

*Specimen type used for PCR: venous whole blood; Specimen type used for Wondfo: fingerstick whole blood.

2.3 Comparison among different specimen types

	,	Wondfo		SD E	Bioline	
Plac			Malaria P.f (HRP2/pLDH)		/hole blood	Test Result (95% CI)
EValua	ation	Tes	st	Positive	Negative	
		Venous whole	Positive	26	0	Sensitivity: 100% (87.13%-100.00%)
Came	Cameroon	blood	Negative	0	30	Specificity: 100% (88.65%-100.00%)
Game		Fingerstick	Positive	26	0	Sensitivity: 100% (87.13%-100.00%)
	whole blood		Negative	0	30	Specificity: 100% (88.65%-100.00%)

2/2

Line at 'C'

and No other line

*Specimen type used for SD Bioline: venous whole blood; Specimen type used for Wondfo: venous whole blood and fingerstick whole blood

Analytical performance study

- 1. The repeatability and reproducibility of Wondfo Malaria P.f (HRP2/pLDH) Test are of good performance demonstrated by in-house panel according to CLSI EP-05 (A3).100% reproducibility was observed in studies within run, between run, between lots, and between sites and operators.
- 2. The following potential interfering substances have no impact on Wondfo Malaria P. f (HRP2/ pLDH) Test.

No.	Туре	Interfering substances
1		НАМА
2	1	Recipient of multiple blood transfusion
3		Anti-dsDNA antibody
4		Anti-cardiolipin antibody IgG
5		Anti-cardiolipin antibody IgM
6		Rheumatoid factors
7		lgG
8		IgM
9	Endogenous	Albumin
10		total bilirubin
11]	Triglyceride
12		Human Chorionic Gonadotropin
13		Cholesterol
14	1	Low density lipoprotein
15]	Haemoglobin
16]	Direct bilirubin
17		Chloroquine Phosphate
18		Artemisinin
19		Amoxicillin
20		Cefalexin
21		Doxycycline Hyclate
22	1	Erythromycin
23	1_	Ibuprofen
24	Exogenous	Piperaquine
25	1	Mebendazole
26		Tribendimidine
27]	Entecavir
28		Rifampicin
29		Aspirin
30		Paracetamol
31		Ethanol
32		Caffeine

The following potential cross-reacting pathogens have no impact on Wondfo Malaria P.f (HRP2/ pLDH) Test.

No.	Туре	Cross-reacting substances	
1		Brucella sp.	
2		HBsAg	
3		Dengue Virus Type 1	
4		HIV-1	
5		HCV	
6		Syphilis	
7		Leishmania sp.	
8	Antigen	Antigen	Leptospira sp.
9	,	M. tuberculosis	
10		Schistosoma sp.	
11		Toxoplasma gondii	
12		Plasmodium vivax	
13		HAV	
14		Measles	
15		Influenza	
16		Tick borne encephalitis	
17		Rubella-IgG	
18	Antibody	Dengue Virus IgG	
19		Cytomegalovirus-IgG	

4. The Limit of Detection of the Wondfo Malaria P.f (HRP2/pLDH) Test for P.f HRP2 (T1 line) and P.f pLDH (T2 line) is 15.63 IU/mL (NIBSC 16/376 1:128) and 31.25 IU/mL (NIBSC 16/376 1:64), respectively.

REFERENCES

- 1. WHO. World Malaria Report 2019, Geneva: World Health Organization; 2019.
- 2. WHO.TSS-3 Malaria rapid diagnostic tests, Geneva: World Health Organization: 2017.
- 3. WHO. TGS-5 Designing instructions for use for in vitro diagnostic medical devices, Geneva: World Health Organization; 2017.
- 4. WHO. Malaria rapid diagnostic test performance. Results of WHO product testing of malaria RDTs: round 7 (2015-2016), Geneva: World Health Organization: 2017.
- 5. WHO. Global technical strategy for malaria

2016–2030, Geneva: World Health Organization; 2015.

SYMBOLS KEY

IVD In vitro diagnostic medical device	Consult instructions for use	Use-by date
$\begin{tabular}{ c c c c } \hline \sum Contains sufficient for tests \end{tabular}$	Date of manufacture	Keep dry
LOT Batch code	Caution	Keep away from Sunlight
Manufacturer	Do not re-use	REF Catalogue number
Temperature limit		

MANUFACTURER INFORMATION

Guangzhou Wondfo Biotech Co. Ltd. No.8 Lizhishan Road, Science City, Huangpu District, 510663, Guangzhou, P.R.China Tel: +86-20-32053962 400-888-5268(Toll Free) Fax: +86-20-32296063 E-mail: global@wondfo.com.cn Website: en.wondfo.com

Please contact the manufacturer or your local distributor if you have any questions about the product.

Language:English

	IFU Version Information					
Rev. A6 (Valid version)	Rel.: 2024/9/5	Minor changes in the limitations of the test and changes in the performance characteristics section.				
Rev. A5	Rel.: 2023/12/22	Supplementation of intended testing population in intended use section and changes in the performance characteristics section.				
Rev. A4	Rel.: 2021/12/16	Supplementation of clinical data in performance characteristics section.				
Rev. A3	Rel.: 2021/9/30	Adjustment of product configurations in kit component section.				
Rev. A2	Rel.: 2021/6/18	Supplementation of clinical data in performance characteristics section				
Rev. A1	Rel.: 2020/7/27	Original version.				

2.2 Quick User Guide



QUICK GUIDE

For fingerstick whole blood

Bring all specimens and kit components to room temperature (15°C- 40°C) before testing. When ready to test, remove the test cassette from the foil pouch by tearing the notch and place it on a flat, dry surface. Label the device with specimen ID number.



1

Wash hands and put on protective gloves before testing. Wipe the fingertip to be lanced with an alcohol prep pad.Select the middle or ring finger for sampling and avoid calloused areas of the finger.



2

Prick the lateral side of fingertip with a lancet. Wipe off the first drop of blood with a sterile cotton swab/ball.Squeeze the fingertip again and allow a new drop of blood to form.







Dip the circular end of the inverted cup into the blood specimen (5μ L).



Fingerstick whole blood should be tested immediately.



Malaria P.f (HRP2/pLDH) Test



- Do not add into buffer well.
- Break off the head of buffer along with the crease line and then twist it off.



- 6
- Add 4 drops of buffer into the buffer well vertically and start timing.



Do not add buffer into the specimen well. Read the results after 15 minutes but no more than 30 minutes.

To avoid confusion, discard the test device after reading the result.



minutes to read the result.

HOW TO INTERPRET THE TEST

Lines that you see	Picture	Read and Interpretation of Results
No line at 'C' (control)	$ \begin{array}{c} \hline C \\ T \\ T \\ T \\ $	Result: Invalid. Action: Take a new cassette and repeat the test.Please contact the local distributor or manufacturer if invalid results continuously appear.
Line at 'C' and No other line	C T2 T1	Result: Negative. Action: No
Line at 'C' and at 'T1' and/or 'T2'	$ \begin{array}{c} 1 \\ C \\ T_2 \\ T_1 \end{array} $ $ \begin{array}{c} C \\ T_2 \\ T_1 \end{array} $ $ \begin{array}{c} C \\ T_2 \\ T_1 \end{array} $	 Result: Positive. 1. Line at 'C', 'T1' and 'T2' indicates positive for P.f HRP2 and P.f pLDH. 2. Line at 'C' and 'T1' indicates positive for P.f HRP2. 3. Line at 'C' and 'T2' indicates positive for P.f pLDH. Note: Line intensity may vary from faint to strong intensity. Consider a faint test line as a positive result. Action: No

DISPOSE

Put all used disposable components into the medical waste container. Dispose according to local infectious waste disposal laws and regulations.